SLPHIGH SIGNALFINANCIAL10-K

SLP reported catastrophic profitability collapse with operating income swinging from $6.1M profit to -$70.7M loss while simultaneously showing strong cash flow improvement and debt reduction.

The massive profitability decline of over 1,250% in operating income indicates either significant one-time charges, major restructuring costs, or fundamental operational deterioration that requires immediate investigation. However, the counterintuitive improvement in operating cash flow by 36% alongside substantial debt reduction suggests these may be non-cash charges rather than core business degradation.

Comparing 2025-12-01 vs 2024-10-30View on EDGAR →
FINANCIAL ANALYSIS

The financial picture presents a stark contradiction with profitability metrics collapsing (operating income down 1,254% and net income down 750%) while liquidity and balance sheet strength improved markedly through cash tripling to $30.9M, debt declining 42%, and operating cash flow rising 36%. The 33% reduction in total assets alongside improved cash generation suggests either major asset write-downs, divestiture activity, or restructuring charges that don't reflect underlying business performance. This divergence between earnings and cash flow performance signals either significant non-cash impairments or a fundamental shift in business operations that investors must scrutinize closely.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-1253.6%
$6.1M-$70.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-750.2%
$10.0M-$64.7M

Net income declined 750.2% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+199.2%
$10.3M$30.9M

Cash position surged 199.2% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
-49.8%
$14.2M$7.1M

Liabilities reduced 49.8% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-44.3%
$12.1M$6.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Debt
Balance Sheet
-41.9%
$5.7M$3.3M

Debt reduced 41.9% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Cash Flow
Cash Flow
+36.1%
$13.3M$18.1M

Operating cash flow surged 36.1% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
-32.9%
$196.6M$131.9M

Total assets contracted 32.9% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-31.6%
$182.4M$124.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
+31%
$39.3M$51.5M

Current assets grew 31% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2025-12-01
PRIOR — 2024-10-30
ADDED
As of November 14, 2025, 20,144,564 shares of the registrant s common stock were outstanding.
The Company is a global leader and premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery and development, clinical trial operations, and commercialization.
The Company supports its clients across the drug development lifecycle from early discovery through all phases of clinical research and development ( R D ), including clinical operations, to product commercialization.
The Company serves clients as a strategic partner throughout the entire drug development lifecycle, offering solutions that integrate scientific software platforms, artificial intelligence-augmented insights, and expert consulting.
This optimizes efficiency, costs, and time-to-market for our clients, thereby enhancing our competitive position.
+7 more — sign up free →
REMOVED
As of October 18, 2024, 20,067,184 shares of the registrant s common stock were outstanding.
We are a global leader and premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization.
With the June 2024 acquisition of Pro-ficiency Holdings, Inc.
and its subsidiaries (collectively, Pro-ficiency ), the Company extended its reach across the drug development value chain from the initial protocol stage through all phases of clinical research and development ( R D ) to product commercialization.
Simulations Plus now has a one-of-a-kind platform to serve its clients at every step in the drug development process.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →